The U.S. Food and Drug Administration has approved Aimmune Therapeutics’s drug that reduces – and potentially eliminates – kids’ allergic reactions to peanuts. According to Fox Business, the pharmaceutical company’s stock was up more than 20 percent as parents [and] their children from ages 4 to 17 received hope on the FDA action.
The news article explains that the drug “arrests any allergic reactions such as anaphylaxis, that occur after exposure to peanuts.” The company explains that allergy sufferers must still maintain a peanut-free diet. The drug is not intended as an emergency treatment.
The FDA approved the first treatment for peanut allergy, a drug that aims to reduce the risk of reactions after an accidental exposure https://t.co/xKH4s7ryIz
— The Wall Street Journal (@WSJ) January 31, 2020
CNN explains that it is designed to “minimize the incidence and severity of a child’s allergic reaction to peanuts, as even a small amount of exposure can be harmful to children with the allergy.”
Aimmune will market the drug under the brand name Palforzia.
